+31.2%
SMR vs MRNA
+153.9%
-122.7%
-93.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -11.8% | -2.2% | -9.6% | -11.5% |
| 7D | -27.9% | -12.7% | -15.2% | -26.6% |
| 30D | -38.9% | -20.7% | -18.2% | -37.1% |
| 3M | -63.0% | +46.3% | -109.2% | -64.8% |
| 6M | -67.7% | +305.2% | -372.9% | -76.9% |
| YTD | -76.3% | +561.2% | -637.5% | -85.6% |
| 1Y | -82.0% | +772.1% | -854.1% | -90.0% |
| 3Y | +31.2% | +147.0% | -115.7% | -21.9% |
| All | +31.2% | +153.9% | -122.7% | -21.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling